FDA Update

On March 13, 2017, the U.S. Food and Drug Administration (FDA) approved ribociclib (Kisqali®, Novartis Pharmaceuticals Corp.), a cyclin-dependent kinase 4/6 inhibitor, in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.

Approval was based on a randomized, double-blind, placebo-controlled, international clinical trial (MONALEESA-2), in post-menopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer who received no prior therapy for advanced disease. A total of 668 patients were randomized to receive either ribociclib plus letrozole (n=334) or placebo plus letrozole (n=334). Ribociclib 600 mg or placebo was administered orally once daily for 21 consecutive days, followed by 7 days off, with letrozole 2.5 mg administered orally once daily for 28 days. Treatment continued until disease progression or unacceptable toxicity.

A pre-planned interim efficacy analysis demonstrated an improvement in PFS (investigator-assessed) with hazard ratio of 0.556 (95% CI: 0.429, 0.720; p<0.0001). The estimated median PFS had not been reached in the ribociclib-containing arm and was 14.7 months in the placebo-containing arm. Objective response rate (ORR) in patients with measurable disease was 52.7% (95% CI: 46.6, 58.9) in the ribociclib plus letrozole arm and 37.1% (95% CI: 31.1, 43.2) in the placebo plus letrozole arm. Overall survival data are immature.

The most common adverse reactions (ARs) observed in 20% or more of patients taking ribociclib were neutropenia, nausea, fatigue, diarrhea, leukopenia, alopecia, vomiting, constipation, headache, and back pain. The most common grade 3 or 4 ARs (reported in >2%) were neutropenia, leukopenia, abnormal liver function tests, lymphopenia, and vomiting. Ribociclib has been shown to prolong the QT interval in a concentration-dependent manner (refer to details in Warning and Precautions section of the label).

The recommended starting dose of ribociclib is 600 mg orally (three 200 mg tablets) taken once daily with or without food for 21 consecutive days followed by 7 days off treatment.

Full prescribing information for ribociclib is available.

FDA granted this application a priority review and breakthrough therapy designation. A description of FDA expedited programs is in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System by completing a form online, by faxing (1-800-FDA-0178) or mailing the postage-paid address form provided online, or by telephone (1-800-FDA-1088).

In collaboration with the FDA and as a service to our members, ONS provides updates on recent FDA approvals and other important FDA actions (e.g., updated safety information, new prescribing information) pertaining to therapies for patients with cancer. This allows the agency to inform oncologists and professionals in oncology-related fields in a timely manner. Included in the FDA updates is a link to the product label or to other sites for additional relevant clinical information. In supplying this information, ONS does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described.

comments

Posted by Kendric Abigail (not verified) 1 week 1 day ago

My Name is Abigail, and am really grateful and thankful for what Dr. ARIBA has done for me and my family. I Was having HIV/ AIDS for good three years with no solution, the diseases almost took my life and cause I was unable to work and I was also loosing lots of money for medication, but one faithful day when I went online, I met lots of testimonies about this great man so I decided to give it a try and to God be the glory he did it. he cured me of my diseases and am so happy and so pleased to Write about him today. if you need his help of you also want to get cured just the way I got mine, just email draribaspelltemple@gmail.com or dr.aribasplltemple@outlook.com, Whatsapp;+2348140439497 and get your healing. He has cure for other deadly diseases like Diabetes, Herpes, Hepatitis of all types and Cancer.

Posted by JONATHAN SPERRY (not verified) 2 days 19 hours ago

These big companies only care about money and profits they could get. They don't care what will be the effect of their greediness to all the people and their surroundings what really causes cancer are all this preserve food they are making, how can a preserve food last for three months, i have been buying preserved food for my kids as a single father because i do not have enough time for my kids due to my job, then suddenly my first daughter feel sick and i quickly run a check on her and discovered she was diagnosed of cancer, as a Doctor i looked for cure but couldn't find any my daughter started taking drugs like her whole life depends on it, it wasn't working the cancer was still spreading i searched more on the internet i found a testimony on how it cured someone then .i copied the email immediately the email ricksimpsoncannabisoil41@gmail.com i wrote to this very email ricksimpsoncannabisoil41@gmail.com, in an hour i got a feedback asking me few questions, and enlightened me on how to get the oil in the next 48hours, i placed my order and in the next 48hours the medication oil got to me in Nairobi Kenya immediately my daughter started using the oil, it been two months now, since my daughter has been using the medication oil and the cancerous problems are gone this very fact was clarified by me and other doctors
i put up this piece of testimony for the sake of those once who need this oil to please don't die in silence their is a cure for your cancer today email: ricksimpsoncannabisoil41@gmail.com and get the oil

Add new comment

About text formats

Plain text

  • No HTML tags allowed.
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.
By submitting this form, you accept the Mollom privacy policy.